Simona Marchitti Selected Research

Uncoupling Protein 2

5/2022	Role of Uncoupling Protein 2 Gene Polymorphisms on the Risk of Ischemic Stroke in a Sardinian Population.
1/2022	Uncoupling Protein 2 as a Pathogenic Determinant and Therapeutic Target in Cardiovascular and Metabolic Diseases.
10/2021	An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation.
6/2020	Brain Overexpression of Uncoupling Protein-2 (UCP2) Delays Renal Damage and Stroke Occurrence in Stroke-Prone Spontaneously Hypertensive Rats.
1/2017	A differential expression of uncoupling protein-2 associates with renal damage in stroke-resistant spontaneously hypertensive rat/stroke-prone spontaneously hypertensive rat-derived stroke congenic lines.
2/2013	Differential modulation of uncoupling protein 2 in kidneys of stroke-prone spontaneously hypertensive rats under high-salt/low-potassium diet.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simona Marchitti Research Topics

Disease

20	Stroke (Strokes) 03/2023 - 01/2007
7	Hypertension (High Blood Pressure) 01/2022 - 08/2015
6	Acute Coronary Syndrome 01/2022 - 05/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 03/2023 - 09/2009
3	Heart Failure 08/2023 - 02/2019
3	Mitochondrial Diseases (Mitochondrial Disease) 04/2023 - 01/2022
3	Ischemic Stroke 05/2022 - 11/2009
3	Atherosclerosis 11/2021 - 09/2009
3	Myocardial Infarction 11/2021 - 08/2016
3	Stable Angina 01/2019 - 05/2012
3	Inflammation (Inflammations) 01/2017 - 02/2013
3	Coronary Artery Disease (Coronary Atherosclerosis) 08/2016 - 05/2012
2	Cardiomyopathies (Cardiomyopathy) 08/2023 - 12/2020
2	Disease Progression 01/2022 - 11/2019
2	Vascular Diseases (Vascular Disease) 10/2021 - 01/2007
2	Atrial Fibrillation 01/2021 - 01/2017
2	Myocardial Ischemia (Ischemic Heart Diseases) 02/2018 - 08/2016
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2017 - 01/2007
2	Vascular Remodeling 09/2009 - 01/2007
1	Neoplasms (Cancer) 08/2023
1	Hypoxia (Hypoxemia) 01/2023
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2023
1	Hypertrophy 01/2023
1	Infarction (Infarctions) 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Ischemia 01/2023
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021
1	Mitral Valve Insufficiency (Mitral Regurgitation) 05/2020
1	digital ulcers 11/2019
1	Systemic Scleroderma (Systemic Sclerosis) 11/2019
1	Body Weight (Weight, Body) 01/2018
1	Proteinuria 01/2018
1	Hypercholesterolemia 08/2016
1	ST Elevation Myocardial Infarction 08/2016
1	Unstable Angina 08/2016
1	Left Ventricular Dysfunction 04/2013
1	Sarcoidosis (Schaumann Disease) 04/2013
1	Pulmonary Arterial Hypertension 04/2013
1	Vascular System Injuries 02/2013
1	Necrosis 02/2013
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2010
1	Cardiomegaly (Heart Hypertrophy) 01/2010
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2010

Drug/Important Bio-Agent (IBA)

14	Atrial Natriuretic Factor (ANF)IBA 04/2023 - 08/2006
8	SaltsIBA 03/2023 - 02/2013
8	Natriuretic PeptidesIBA 01/2023 - 08/2006
8	Proteins (Proteins, Gene)FDA Link 06/2020 - 11/2009
6	Uncoupling Protein 2IBA 05/2022 - 02/2013
5	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2023 - 09/2009
3	Messenger RNA (mRNA)IBA 01/2022 - 08/2015
3	AntioxidantsIBA 01/2019 - 02/2013
3	PotassiumIBA 01/2017 - 02/2013
2	Electron Transport Complex I (NADH-CoQ Reductase)IBA 01/2020 - 01/2019
2	Brain Natriuretic Peptide (Natrecor)FDA Link 02/2019 - 08/2006
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 02/2016
2	SodiumIBA 01/2017 - 07/2015
2	Biomarkers (Surrogate Marker)IBA 04/2016 - 04/2013
1	Sirtuin 3IBA 08/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2023
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	Antihypertensive Agents (Antihypertensives)IBA 01/2023
1	N-propionylprocainamideIBA 01/2023
1	NADH DehydrogenaseIBA 01/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	CalciumIBA 01/2022
1	Stromal Interaction Molecule 1IBA 01/2022
1	TrehaloseIBA 11/2021
1	DisaccharidesIBA 11/2021
1	SphingolipidsIBA 04/2021
1	LipidsIBA 04/2021
1	5-nitro-2-(3-phenylpropylamino)benzoic acidIBA 12/2020
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2020
1	ThymineIBA 01/2020
1	Nicotinamide MononucleotideIBA 01/2020
1	erucylphosphocholineIBA 01/2020
1	NAD (NADH)IBA 01/2020
1	Beclin-1IBA 01/2020
1	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2020
1	N-terminal proatrial natriuretic peptideIBA 11/2019
1	Peptide Hydrolases (Proteases)FDA Link 02/2019
1	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 02/2019
1	FurinIBA 02/2019
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2018
1	Valsartan (Vals)FDA Link 01/2018
1	Neprilysin (Neutral Endopeptidase)IBA 01/2018
1	Type 1 Angiotensin ReceptorIBA 01/2018
1	AnionsIBA 01/2017
1	Fenofibrate (CiL)FDA LinkGeneric 01/2017
1	pro-brain natriuretic peptide (1-76)IBA 04/2016
1	Sirtuin 1IBA 08/2015
1	Carbon MonoxideIBA 04/2013
1	MicroRNAs (MicroRNA)IBA 02/2013
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 11/2009
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 11/2009

Therapy/Procedure

2	Percutaneous Coronary Intervention 02/2018 - 04/2016
1	Secondary Prevention 01/2021
1	Therapeutics 02/2018
1	Stents 04/2016